Peps
What is Vasopressin?
Arginine vasopressin is a nine-residue hormone involved in water balance and vascular tone. VASST compared vasopressin with norepinephrine in septic shock.
Biological role or research focus
Fluid balance and vasopressor research.
An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Role reference: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Names you may encounter
Arginine vasopressin · AVP
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Endogenous nonapeptide hormone
- Research focus
- Fluid balance and vasopressor research
- Featured evidence
- Human randomized trial
- Source check
- October 4, 2026
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Molecular structure
How Vasopressin works
Vasopressin pathways connect water retention with vascular effects. A physiologic receptor effect does not automatically translate into a survival advantage in critical illness.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Medicine status & clinical context
The U.S. Vasostrict label concerns adults with vasodilatory shock whose low blood pressure persists despite fluids and catecholamines. This hospital vasopressor use is distinct from the natural hormone’s role in water balance.
The featured study concerns supervised vasopressor treatment in septic shock. It is not research on general hydration, longevity, or consumer supplementation.
Source: DailyMed · Vasostrict prescribing information ↗
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2008
VASST
Did vasopressin reduce overall mortality versus norepinephrine?
- Population / model
- 778 patients with septic shock who were already receiving vasopressors.
- Study design
- Randomized blinded comparison of vasopressin and norepinephrine, with 28- and 90-day mortality outcomes.
- Main finding
- Mortality at 28 days was 35.4% versus 39.3% (P=0.26). At 90 days it was 43.9% versus 49.6% (P=0.11). Neither overall comparison was statistically significant.
- Limits & context
- An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Vasopressin. ↗
· 2006 · Review
Optimizing Vasopressin Use and Initiation Timing in Septic Shock: A Narrative Review. ↗
Chest · 2023 Nov · Journal Article, Review, Research Support, N.I.H., Extramural
Read available full text ↗
Vasopressin. ↗
Seminars in respiratory and critical care medicine · 2004 Dec · Journal Article
The Biology of Vasopressin. ↗
Biomedicines · 2021 Jan 18 · Journal Article, Review
Read available full text ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
What the featured evidence can tell us
Vasopressor effects require close clinical monitoring. The selected trial cannot support unsupervised use or establish safety in healthy people.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Identity, route, and evidence limits
An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Official product context · checked October 4, 2026
The label describes reduced cardiac output, rhythm disturbances, low sodium, and ischemia. Increasing blood pressure is not, by itself, proof of a survival benefit.
Source: DailyMed · Vasostrict prescribing information ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Was vasopressin proven to reduce overall mortality?
- What population, comparator, and route were actually studied?
- An apparent subgroup difference in less severe shock does not establish overall mortality superiority. Critical-care treatment context limits application to other populations.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Was vasopressin proven to reduce overall mortality?
No. The overall mortality comparisons in VASST were not statistically significant. Subgroup results should not replace the primary overall finding.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Does this page establish a supplier’s product quality?
No. A publication describes its own tested material. It does not verify a supplier listing, batch identity, purity, or clinical suitability.
Source: Vasopressin versus norepinephrine infusion in patients with septic shock. · 2008 ↗
Does the official medicine reference cover every use discussed online?
No. The reference covers defined products and clinical settings. Research outside those uses needs separate evidence and does not extend the medicine’s authorization.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.